
Michael Jones talks to AstraZeneca’s CPO Jon Kirby about some of the unexpected benefits of the downturn. In their discussion they focus on the harsh protectionism, trade disputes and increasing tariffs that have led to numerous opportunities, as well as lower price estimates, smaller supply bases and reduced supplier costs.